Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
Acquisition of CDK4/6i resistance represents a major clinical challenge. Here, the authors report that inhibition of CK1ε can prevent acquisition of CDK4/6i resistance, potentiating the therapeutic efficacy of CDK4/6i in human breast cancer.
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-09-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-25700-6 |
id |
doaj-88efe8ceb62e4eb287e6888a694cafe6 |
---|---|
record_format |
Article |
spelling |
doaj-88efe8ceb62e4eb287e6888a694cafe62021-09-12T11:45:59ZengNature Publishing GroupNature Communications2041-17232021-09-0112111510.1038/s41467-021-25700-6Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancerFabin Dang0Li Nie1Jin Zhou2Kouhei Shimizu3Chen Chu4Zhong Wu5Anne Fassl6Shizhong Ke7Yuangao Wang8Jinfang Zhang9Tao Zhang10Zhenbo Tu11Hiroyuki Inuzuka12Piotr Sicinski13Adam J. Bass14Wenyi Wei15Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Liver Surgery & Liver Transplantation, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan UniversityDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical SchoolDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical SchoolDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical SchoolDivision of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical SchoolProgram in Cellular and Molecular Medicine, Boston Children’s HospitalDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDepartment of Cancer Biology, Dana-Farber Cancer Institute and Department of Genetics, Blavatnik Institute, Harvard Medical SchoolDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical SchoolDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolAcquisition of CDK4/6i resistance represents a major clinical challenge. Here, the authors report that inhibition of CK1ε can prevent acquisition of CDK4/6i resistance, potentiating the therapeutic efficacy of CDK4/6i in human breast cancer.https://doi.org/10.1038/s41467-021-25700-6 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fabin Dang Li Nie Jin Zhou Kouhei Shimizu Chen Chu Zhong Wu Anne Fassl Shizhong Ke Yuangao Wang Jinfang Zhang Tao Zhang Zhenbo Tu Hiroyuki Inuzuka Piotr Sicinski Adam J. Bass Wenyi Wei |
spellingShingle |
Fabin Dang Li Nie Jin Zhou Kouhei Shimizu Chen Chu Zhong Wu Anne Fassl Shizhong Ke Yuangao Wang Jinfang Zhang Tao Zhang Zhenbo Tu Hiroyuki Inuzuka Piotr Sicinski Adam J. Bass Wenyi Wei Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer Nature Communications |
author_facet |
Fabin Dang Li Nie Jin Zhou Kouhei Shimizu Chen Chu Zhong Wu Anne Fassl Shizhong Ke Yuangao Wang Jinfang Zhang Tao Zhang Zhenbo Tu Hiroyuki Inuzuka Piotr Sicinski Adam J. Bass Wenyi Wei |
author_sort |
Fabin Dang |
title |
Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer |
title_short |
Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer |
title_full |
Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer |
title_fullStr |
Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer |
title_full_unstemmed |
Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer |
title_sort |
inhibition of ck1ε potentiates the therapeutic efficacy of cdk4/6 inhibitor in breast cancer |
publisher |
Nature Publishing Group |
series |
Nature Communications |
issn |
2041-1723 |
publishDate |
2021-09-01 |
description |
Acquisition of CDK4/6i resistance represents a major clinical challenge. Here, the authors report that inhibition of CK1ε can prevent acquisition of CDK4/6i resistance, potentiating the therapeutic efficacy of CDK4/6i in human breast cancer. |
url |
https://doi.org/10.1038/s41467-021-25700-6 |
work_keys_str_mv |
AT fabindang inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT linie inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT jinzhou inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT kouheishimizu inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT chenchu inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT zhongwu inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT annefassl inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT shizhongke inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT yuangaowang inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT jinfangzhang inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT taozhang inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT zhenbotu inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT hiroyukiinuzuka inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT piotrsicinski inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT adamjbass inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer AT wenyiwei inhibitionofck1epotentiatesthetherapeuticefficacyofcdk46inhibitorinbreastcancer |
_version_ |
1717755490269659136 |